2023
Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018)
Shahrir S, Crothers K, McGinnis K, Chan K, Baeten J, Wilson S, Butt A, Pisani M, Baldassarri S, Justice A, Williams E. Receipt of Smoking Cessation Medications Among People With and Without Human Immunodeficiency Virus in the Veterans Aging Cohort Study (2003–2018). Open Forum Infectious Diseases 2023, 10: ofad089. PMID: 36968969, PMCID: PMC10034589, DOI: 10.1093/ofid/ofad089.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyAging Cohort StudyHuman immunodeficiency virusCessation medicationsCohort studyCurrent smokersCurrent smokingHIV statusImmunodeficiency virusRelative riskHuman immunodeficiency virus statusSmoking cessation medicationsNicotine replacement therapyRates of receiptDangers of smokingOutpatient prescriptionsReplacement therapyPharmacy dataVirus statusTobacco useAnnual rateMedicationsSmokingPWHStatistical differenceEnhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2022
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus
Oursler KK, Marconi VC, Wang Z, Xu K, Montano M, So-Armah K, Justice AC, Sun YV. Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus. Clinical Infectious Diseases 2022, 76: e638-e644. PMID: 35970820, PMCID: PMC10169393, DOI: 10.1093/cid/ciac656.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPhysiologic frailtyVACS IndexCause mortalityMortality discriminationImmunodeficiency virusAge accelerationEpigenetic age accelerationVeterans Aging Cohort Study (VACS) IndexWhite blood cell samplesVACS Index 2.0VACS Index scoreNon-Hispanic blacksIntrinsic epigenetic age accelerationExtrinsic epigenetic age accelerationEpigenome-wide DNA methylationBlood cell samplesHazard ratioOne-year increaseCox regressionMean ageC-statisticIndex scoreMortalityStudy indices
2021
Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, Lima VD, Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo KA, Mayor A, Tate JP, Benson C, Bosch R, Kirk G, Marconi V, Colasanti J, Mayer K, Grasso C, Hogg R, Lima V, Montaner J, Sereda P, Salters K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Jacobson J, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Smith G, Loutfy M, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, McGinnis K, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases 2021, 75: 297-304. PMID: 34609485, PMCID: PMC9410720, DOI: 10.1093/cid/ciab883.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationVACS Index 2.0National Death IndexHIV-1 RNAHuman immunodeficiency virusCopies/mLRisk of mortalityRace/ethnicityCohort CollaborationNA-ACCORDCause mortalityCD4 countMedian ageDeath IndexImmunodeficiency virusPredicting MortalityMortality ascertainmentMortality rateMortalitySpecific biomarkersPWHDiverse cohortObserved mortalityCohortHIVProstate Cancer Screening and Incidence among Aging Persons Living with HIV
Leapman MS, Stone K, Wadia R, Park LS, Gibert CL, Goetz MB, Bedimo R, Rodriguez-Barradas M, Shebl F, Justice AC, Brown ST, Crothers K, Sigel KM. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. Journal Of Urology 2021, 207: 324-332. PMID: 34555924, PMCID: PMC8741750, DOI: 10.1097/ju.0000000000002249.Peer-Reviewed Original ResearchConceptsPSA testingHIV statusProstate cancerProstate biopsyCancer incidenceHuman immunodeficiency virus statusProstate-specific antigen (PSA) testingVeterans Aging Cohort StudyProspective national cohortMultivariable Poisson modelsAging Cohort StudySpecific antigen testingHuman immunodeficiency virusProstate cancer screeningUninfected comparatorsCohort studyIncident cancerAntigen testingImmunodeficiency virusMean ageCancer screeningNational cohortCancer stageVirus statusMultivariable model
2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original ResearchDNA methylation biomarker selected by an ensemble machine learning approach predicts mortality risk in an HIV-positive veteran population
Shu C, Justice AC, Zhang X, Marconi VC, Hancock DB, Johnson EO, Xu K. DNA methylation biomarker selected by an ensemble machine learning approach predicts mortality risk in an HIV-positive veteran population. Epigenetics 2020, 16: 741-753. PMID: 33092459, PMCID: PMC8216205, DOI: 10.1080/15592294.2020.1824097.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyMortality risk groupsAging Cohort StudyHigher mortality riskMortality riskRisk groupsCohort studyHigh mortality risk groupLow-mortality risk groupsInflammation response pathwayHIV-positive participantsHuman immunodeficiency virusLow-risk groupImproved life expectancyVACS IndexHIV populationNatural killerImmunodeficiency virusPredictive biomarkersPLWHDNA methylation biomarkersVeteran populationSurvival analysisEpigenome-wide associationHIVThe Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs
Reddon H, Grant C, Nosova E, Fairbairn N, Barrios R, Justice AC, Nolan S, Socias ME, Milloy MJ. The Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs. Clinical Infectious Diseases 2020, 73: 538-541. PMID: 32857842, PMCID: PMC8496478, DOI: 10.1093/cid/ciaa1263.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVeterans Aging Cohort Study (VACS) IndexHuman immunodeficiency virus (HIV) disease severityStudy indicesCommunity-recruited cohortIllicit drugsVirus disease severityVACS IndexProspective cohortImmunodeficiency virusClinical biomarkersDisease severityStudy periodCohortMortalityDrugsIndexBiomarkersSeverityTiming of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus
Silverberg MJ, Leyden W, Hernández-Ramírez RU, Qin L, Lin H, Justice AC, Hessol NA, Achenbach CJ, D’Souza G, Engels EA, Althoff KN, Mayor AM, Sterling TR, Kitahata MM, Bosch RJ, Saag MS, Rabkin CS, Horberg MA, Gill MJ, Grover S, Mathews WC, Li J, Crane HM, Gange SJ, Lau B, Moore RD, Dubrow R, Neugebauer RS. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2020, 72: 1900-1909. PMID: 32785640, PMCID: PMC8315132, DOI: 10.1093/cid/ciaa1046.Peer-Reviewed Original ResearchConceptsVirus-related cancersEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapyART initiationImmunodeficiency virusNorth American AIDS Cohort CollaborationART-naive PLWHEarly ART initiationAntiretroviral therapy initiationHIV transmission riskNon-Hodgkin lymphomaCancer registry linkageRisk of cancerMarginal structural modelsRace/ethnicityCohort CollaborationTherapy initiationChart reviewIncident cancerRegistry linkageViral hepatitisTime-dependent confoundingCancer groupViral etiology
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack menNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection
Hanberg JS, Freiberg MS, Goetz MB, Rodriguez-Barradas MC, Gibert C, Oursler KA, Justice AC, Tate JP. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. Open Forum Infectious Diseases 2019, 6: ofz347. PMID: 31660334, PMCID: PMC6786514, DOI: 10.1093/ofid/ofz347.Peer-Reviewed Original ResearchHuman immunodeficiency virusVACS Index 2.0Veterans Aging Cohort StudyAddition of NLRHepatic decompensationLymphocyte ratioHepatitis C virusInflammatory biomarkersImmunodeficiency virusHepatitis C virus statusHIV/HCV coinfectionC virus statusPrognostic inflammatory biomarkerSoluble CD-14Strong unadjusted associationsAging Cohort StudyBiomarkers of inflammationPoor health outcomesMortality risk indexHCV coinfectionAntiretroviral therapyCohort studyBiomarker cohortD-dimerPrognostic indexAssociation of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, Benson C, Bosch R, Kirk G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Rabkin C, Margolick J, Jacobson L, D’Souza G, Klein M, Kroch A, Burchell A, Betts A, Lindsay J, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Mathews W, Eron J, Napravnik S, Kitahata M, Crane H, Drozd D, Sterling T, Haas D, Rebeiro P, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Freeman A, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Lee J, You B, Hogan B, Zhang J, Jing J, Humes E, Coburn S. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases 2019, 70: 1176-1185. PMID: 31044245, PMCID: PMC7319056, DOI: 10.1093/cid/ciz329.Peer-Reviewed Original ResearchConceptsAnal cancer riskHIV RNA measuresCancer riskPeak CD4North American AIDS Cohort CollaborationRNA measuresHIV-1 RNA levelsHuman immunodeficiency virus (HIV) viremiaOncogenic human papillomavirus (HPV) infectionAnal cancer developmentAssociation of immunosuppressionTime-updated CD4T-cell countsHuman papillomavirus infectionHuman immunodeficiency virusCohort CollaborationPapillomavirus infectionImmunodeficiency virusImmunoregulatory controlCD4Cox modelCancer promotionUseful markerCancer developmentRNA levelsEffect estimates in randomized trials and observational studies: comparing apples with apples
Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA. Effect estimates in randomized trials and observational studies: comparing apples with apples. American Journal Of Epidemiology 2019, 188: 1569-1577. PMID: 31063192, PMCID: PMC6670045, DOI: 10.1093/aje/kwz100.Peer-Reviewed Original Research
2017
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States
Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, Rebeiro PF, Koethe JR, Martin JN, Horberg MA, Boyd CM, Kitahata MM, Crane HM, Gebo KA, Gill MJ, Silverberg MJ, Palella FJ, Patel P, Samji H, Thorne J, Rabkin CS, Mayor A, Althoff KN, Freeman A, Cescon A, Rachlis A, Rogers B, Rodriguez B, Grasso C, Benson C, Drozd D, Fiellin D, Haas D, Kirk G, Willig J, Globerman J, Brooks J, Eron J, Montaner J, Gabler K, Anastos K, Mayer K, Jacobson L, Kopansky-Giles M, Klein M, Turner M, Mugavero M, Saag M, Harrigan P, Dubrow R, Hunter-Mellado R, Hogg R, Bosch R, McKaig R, Bebawy S, Rourke S, Napravnik S, Boswell S, Sterling T. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases 2017, 66: 1230-1238. PMID: 29149237, PMCID: PMC5889007, DOI: 10.1093/cid/cix998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBlack PeopleCohort StudiesDiabetes Mellitus, Type 2FemaleHeterosexualityHIVHIV InfectionsHomosexuality, MaleHumansHypercholesterolemiaHypertensionLongitudinal StudiesMaleMiddle AgedMultimorbidityRenal Insufficiency, ChronicSexual and Gender MinoritiesUnited StatesWhite PeopleConceptsHuman immunodeficiency virusAdjusted prevalence ratiosAge-associated conditionsImmunodeficiency virusMultimorbidity prevalenceClinical careNorth American AIDS Cohort CollaborationEnd-stage liver diseaseMedian baseline ageHIV outpatient clinicChronic kidney diseaseRobust error varianceConfidence intervalsComplex healthcare needsDemographic subgroupsCohort CollaborationComorbidity preventionCohort studyDiabetes mellitusLiver diseaseOutpatient clinicKidney diseasePrevalence ratiosBaseline ageCare complexityMistrust and Endorsement of Human Immunodeficiency Virus Conspiracy Theories Among Human Immunodeficiency Virus–Infected African American Veterans
Mattocks KM, Gibert C, Fiellin D, Fiellin LE, Jamison A, Brown A, Justice AC. Mistrust and Endorsement of Human Immunodeficiency Virus Conspiracy Theories Among Human Immunodeficiency Virus–Infected African American Veterans. Military Medicine 2017, 182: e2073-e2079. PMID: 29087885, DOI: 10.7205/milmed-d-17-00078.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV conspiracy beliefsAfrican American veteransHealthcare providersHIV treatmentVeterans Health Administration (VHA) careAmerican veteransPoor health outcomesGovernment healthcare providersPhysician mistrustHIV careVHA hospitalsImmunodeficiency virusTreatment recommendationsMedical conditionsPotential cureHealth outcomesHIV conspiracy theoriesSemistructured interview formatVeterans' willingnessDisproportionate tollRacial disparitiesHealthcare systemVeterans' beliefsVeteransRisk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status
Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Re V. Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. Clinical Infectious Diseases 2017, 65: 1542-1550. PMID: 29020184, PMCID: PMC5850026, DOI: 10.1093/cid/cix564.Peer-Reviewed Original ResearchConceptsSevere acute liver injuryAcute liver injuryHuman immunodeficiency virusStatin initiatorsLower riskHCV statusCohort studyHazard ratioStatin nonusersLiver injuryUninfected personsImmunodeficiency virusChronic hepatitis C virus (HCV) infectionHepatitis C virus (HCV) infection statusHIV/HCV-coinfected patientsPropensity score-adjusted hazard ratiosHIV/HCV statusHepatitis C virus infectionVeterans Aging Cohort StudyC virus infectionAging Cohort StudyConfidence intervalsVirus infection statusDevelopment of liverAminotransferase elevationCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers
Shiels MS, Althoff KN, Pfeiffer RM, Achenbach CJ, Abraham AG, Castilho J, Cescon A, D’Souza G, Dubrow R, Eron JJ, Gebo K, Gill M, Goedert JJ, Grover S, Hessol NA, Justice A, Kitahata M, Mayor A, Moore RD, Napravnik S, Novak RM, Thorne JE, Silverberg MJ, Engels EA, AIDS F. HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clinical Infectious Diseases 2017, 64: 468-475. PMID: 27940936, PMCID: PMC5850313, DOI: 10.1093/cid/ciw764.Peer-Reviewed Original ResearchConceptsOral cavity/pharynxYounger ageCancer diagnosisCD4 countMedian ageLung cancerKidney cancerGeneral populationNorth American AIDS Cohort CollaborationMost cancersEnd Results ProgramHuman immunodeficiency virusRisk factor exposureLung cancer diagnosisAccelerated cancer progressionCohort CollaborationNon-AIDSAnal cancerHIV infectionImmunodeficiency virusResults ProgramMyeloma diagnosisPLWHAIDS statusCancer
2016
First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013
Wong C, Gange SJ, Buchacz K, Moore RD, Justice AC, Horberg MA, Gill MJ, Koethe JR, Rebeiro PF, Silverberg MJ, Palella FJ, Patel P, Kitahata MM, Crane HM, Abraham AG, Samji H, Napravnik S, Ahmed T, Thorne JE, Bosch RJ, Mayor AM, Althoff KN, Research and Design F. First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000–2013. Clinical Infectious Diseases 2016, 64: 459-467. PMID: 28172581, PMCID: PMC5850614, DOI: 10.1093/cid/ciw804.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseHuman immunodeficiency virusDiabetes mellitusAntiretroviral therapyCumulative incidenceKidney diseaseNoncommunicable diseasesNorth American AIDS Cohort CollaborationOccurrence of DMType 2 diabetes mellitusRisk of deathDemographic subgroupsNon-black womenCohort CollaborationHIV populationImmunodeficiency virusTreatment optionsHypertensionAge 70Poisson regressionRacial disparitiesDiseaseBlack womenIncidenceCareEfavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimen